Moderna, Inc. Announces $3.0B Convertible Note Offering Due 2032

What Happened
Moderna announced it completed a private offering of $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due March 1, 2032 (the “Notes”) on September 1, 2026, including the initial purchasers’ full exercise of an option to increase the offering. The Notes were issued under an indenture with U.S. Bank Trust Company, N.A. as trustee. The Company also entered into capped call transactions with financial institutions to reduce potential dilution upon conversion.

Key Details

• Aggregate principal: $3,000,000,000; maturity date: March 1, 2032. Notes are general senior unsecured obligations.
• Interest and conversion: Notes bear no regular interest; special interest accrues only in specified circumstances. Initial conversion rate = 4.7487 shares per $1,000 principal (≈ $210.58 per share), a ~47.5% premium to Moderna’s $142.77 closing price on Aug 27, 2026.
• Proceeds and costs: Net proceeds ≈ $2,957.3 million. Moderna used $328.8 million to pay for the capped call transactions; remaining proceeds for general corporate purposes (including oncology growth and possible debt repayment).
• Capped calls and caps: Capped call transactions cover the shares underlying the Notes, limiting dilution and offsetting certain cash payments; initial cap price ≈ $392.62 per share (≈175% premium to $142.77). Redemption/conversion mechanics: conversions allowed upon specified stock-price or other triggering events before Dec 1, 2031 and anytime from Dec 1, 2031 until shortly before maturity; company limited from redeeming notes before Sept 6, 2029 (except cleanup redemptions).

Why It Matters
This filing creates a sizable new convertible debt obligation on Moderna’s balance sheet through 2032 and provides ~ $2.96B of net capital. The convertible structure and capped calls are intended to limit dilution to existing shareholders but still allow conversion into shares under defined conditions. Investors should note the conversion price premium, the capped call cost, and the timing/conditions under which conversion or redemption can occur—factors that affect potential dilution, cash flow (if special interest or redemptions occur), and capital allocation (including planned use for oncology investment and debt repayment).